Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
AstraZeneca
Seagen Inc.
Ono Pharmaceutical Co. Ltd
AstraZeneca
Massachusetts General Hospital
Bayer
The First Affiliated Hospital with Nanjing Medical University
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
H. Lee Moffitt Cancer Center and Research Institute
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
I-Mab Biopharma US Limited
Seagen Inc.
The First Affiliated Hospital with Nanjing Medical University
AstraZeneca
Baylor College of Medicine
Ruijin Hospital
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
The First Affiliated Hospital with Nanjing Medical University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hoffmann-La Roche
Daiichi Sankyo
SOFIE
University of Washington
Samsung Medical Center
Shanghai Zhongshan Hospital
Rutgers, The State University of New Jersey
ImmunityBio, Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Beijing Friendship Hospital
The First Affiliated Hospital with Nanjing Medical University
China Medical University, China
Massachusetts General Hospital
Genome & Company
Samsung Medical Center
Cedars-Sinai Medical Center
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Guangdong Provincial People's Hospital
Hospital General de Mexicali
Nizhny Novgorod Regional Clinical Oncology Center
National Institutes of Health Clinical Center (CC)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Astellas Pharma Inc